Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-05-28Clinical Trial Update: PHA-739358 for Treatment of Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 clinical trial update of PHA-739358 in metastatic castration-resistant prostate cancer; study completed.
-
CLINICAL_TRIALS trial_result · 2014-05-26Clinical Trial Update: A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 1]
A Phase 1 study of CNTO 328 (siltuximab) in patients with metastatic hormone-refractory prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2014-05-07Clinical Trial Update: A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases [Phase 3]
Phase III trial evaluating Radium-223 dichloride in symptomatic hormone-refractory prostate cancer with skeletal metastases completed; resul…
-
CLINICAL_TRIALS trial_result · 2014-04-30Clinical Trial Update: A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 trial assessing the short-term safety of continuous dosing of abiraterone acetate with prednisone under modified fasting and fed sta…
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]
Phase 1 safety study of repeated dosing with a cytotoxic lymphocyte–based therapy for hormone-refractory prostate cancer, with results poste…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients [Phase 2]
A Phase 2 study evaluating single-agent temsirolimus (Torisel) in chemotherapy-naïve castration-resistant prostate cancer; results were post…
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating sorafenib to overcome resistance to systemic chemotherapy in androgen-independent (castration-resistant) prostate…
-
CLINICAL_TRIALS trial_result · 2014-03-10Clinical Trial Update: AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer [Phase 1, Phase 2]
This entry reports the completion of a Phase 1/2 clinical trial evaluating AMG 102 in combination with mitoxantrone and prednisone in men wi…
-
CLINICAL_TRIALS trial_result · 2014-03-03Clinical Trial Update: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 study evaluated the combination of everolimus (RAD001) with docetaxel in metastatic castration-resistant prostate cancer; the tr…
-
CLINICAL_TRIALS trial_result · 2014-02-06Clinical Trial Update: Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer [Phase 3]
Phase 3 randomized trial comparing docetaxel plus dasatinib vs docetaxel plus placebo in castration-resistant prostate cancer; results were …
-
CLINICAL_TRIALS trial_result · 2014-01-08Clinical Trial Update: A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer [Phase 2]
The document reports a Phase 2 safety study of ZD4054 (zibotentan) in patients with metastatic hormone-resistant prostate cancer; the trial …
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer [Phase 2]
This phase 2 trial compared continuing docetaxel versus switching to cabazitaxel after a minor PSA response in metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2013-12-11Clinical Trial Update: Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating the combination of oxaliplatin and pemetrexed disodium in patients with refractory hormone-resistant pro…
-
CLINICAL_TRIALS trial_result · 2013-12-05Clinical Trial Update: Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) [Phase 2]
Clinical Trial Update reporting a Phase II study of Hamsa-1 in metastatic castration-resistant prostate cancer, sponsored by Tiltan Pharma L…
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001
Clinical trial update reporting molecular, genetic, and genomic assessments from patients with metastatic castration-resistant prostate canc…
-
CLINICAL_TRIALS trial_result · 2013-11-27Clinical Trial Update: Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 trial evaluated dasatinib in combination with docetaxel for metastatic hormone-refractory prostate cancer; results were posted i…
-
CLINICAL_TRIALS trial_result · 2013-10-17Clinical Trial Update: Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer [Phase 2]
This update reports the results of a Phase 2 trial of erlotinib as a single agent in chemotherapy-naive androgen-independent (castration-res…
-
CLINICAL_TRIALS trial_result · 2013-10-10Clinical Trial Update: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer [Phase 3]
A Phase 3 trial evaluating aflibercept in combination with docetaxel for metastatic castration-resistant prostate cancer has completed with …
-
CLINICAL_TRIALS trial_result · 2013-09-24Clinical Trial Update: Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer [Phase 3]
An extension study assessing the long-term safety of denosumab in patients undergoing androgen deprivation therapy for non-metastatic prosta…
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer [Phase 3]
A Phase 3 trial evaluating lenalidomide in combination with docetaxel and prednisone in castration-resistant prostate cancer completed, with…
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects [Phase 1]
Phase 1 study comparing enzalutamide capsule vs tablet for relative bioavailability after a single fasted dose in healthy male subjects; the…
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate [Phase 2]
A Phase II trial evaluating a radiolabeled monoclonal antibody for progressive metastatic castration-resistant prostate cancer has completed…
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer [Phase 2]
Phase 2 trial evaluating samarium-153-EDTMP with or without PSA/TRICOM vaccine in men with androgen-insensitive (castration-resistant) prost…
-
CLINICAL_TRIALS trial_result · 2013-06-19Clinical Trial Update: Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer [Phase 2]
Phase 2 clinical trial update of perifosine for metastatic, androgen-independent prostate cancer; the study has completed.
-
CLINICAL_TRIALS trial_result · 2013-06-07Clinical Trial Update: A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 study to determine the maximum tolerated dose of ASG-5ME in patients with castration-resistant prostate cancer.